Focus Care Pharmaceuticals and Axxelent Pharma Science Forge Strategic Collaboration for Generic Product  Development and Marketing in Dutch and European Markets.

Zaandam, Netherlands, May 27, 2024 – Focus Care Pharmaceuticals (“Focus Care”), a rapidly growing and  quality-centric generic pharmaceutical company based in Zaandam, Netherlands, and Axxelent Pharma Science  (“Axxelent”), a research-driven pharmaceutical firm headquartered in Chennai, India, have entered into a  strategic partnership. This collaboration aims to develop and market generic products for the Dutch and  broader European markets. 

Focus Care is dedicated to delivering affordable, safe, and effective medications to the Dutch market. Axxelent,  with its focus on the development and manufacturing of complex oral solid dosage forms, oral liquids, topical  dosage forms, ophthalmic products, and injectables for regulated markets, prides itself on its commitment to  collaboration, value, and compliance. 

“In this new and thriving phase at Focus Care, we are thrilled to partner with Axxelent, a company that shares  our core values. While our primary market is the Netherlands, we are also exploring the potential to expand  our reach across Europe,” said Maurits Haasnoot, Owner and CEO of Focus Care Pharmaceuticals. 

Jitesh Devendra, Co-Founder and Chairman of Axxelent, echoed this enthusiasm: “Focus Care aims to be a  leading generic player in the Dutch and possibly European market, and Axxelent strives to be a reliable partner  for the development and supply of products. Our shared visions make this collaboration complementary and  synergistic.” 

Both companies believe that their combined efforts will yield greater results than they could achieve  individually. This groundbreaking partnership marks the start of an exciting journey, with both firms eager to  leverage their expertise to develop high-quality, affordable, and accessible products for their customers. 

For more information on Focus Care, please visit focuscare.nl. 

For more information on Axxelent Pharma Science, please visit axxelent.com.